Faculty	O
of	O
Medicine	O
and	O
Health	O
Technology	O
Tays	O
Cancer	O
Centre	O
Tampere	O
University	O
P.O.	O
Box	O
100	O
FI-33014	O
Tampere	O
Finland	O
Department	O
of	O
Oncology	O
Tampere	O
University	O
Hospital	O
P.O.	O
Box	O
2000	O
FI-33521	O
Tampere	O
Finland	O
EmiliaAKorhonen	B-authors

Faculty	O
of	O
Medicine	O
and	O
Health	O
Technology	O
Tays	O
Cancer	O
Centre	O
Tampere	O
University	O
P.O.	O
Box	O
100	O
FI-33014	O
Tampere	O
Finland	O
Department	O
of	O
Oncology	O
Tampere	O
University	O
Hospital	O
P.O.	O
Box	O
2000	O
FI-33521	O
Tampere	O
Finland	O
OutiLahdenperä	B-authors
PiaVihinen	B-authors
ArjaJukkola	B-authors
PeeterKarihtala	B-authors
SonjaAho	O
Department	O
of	O
Oncology	O

Faculty	O
of	O
Medicine	O
and	O
Health	O
Technology	O
Tays	O
Cancer	O
Centre	O
Tampere	O
University	O
P.O.	O
Box	O
100	O
FI-33014	O
Tampere	O
Finland	O
Department	O
of	O
Oncology	O
Tampere	O
University	O
Hospital	O
P.O.	O
Box	O
2000	O
FI-33521	O
Tampere	O
Finland	O
EevaMoilanen	B-authors
KariAlitalo	B-authors

Faculty	O
of	O
Medicine	O
and	O
Health	O
Technology	O
Tays	O
Cancer	O
Centre	O
Tampere	O
University	O
P.O.	O
Box	O
100	O
FI-33014	O
Tampere	O
Finland	O
Department	O
of	O
Oncology	O
Tampere	O
University	O
Hospital	O
P.O.	O
Box	O
2000	O
FI-33521	O
Tampere	O
Finland	O

Faculty	O
of	O
Medicine	O
and	O
Health	O
Technology	O
Tays	O
Cancer	O
Centre	O
Tampere	O
University	O
P.O.	O
Box	O
100	O
FI-33014	O
Tampere	O
Finland	O
Department	O
of	O
Oncology	O
Tampere	O
University	O
Hospital	O
P.O.	O
Box	O
2000	O
FI-33521	O
Tampere	O
Finland	O
EmiliaAKorhonen	B-authors

Faculty	O
of	O
Medicine	O
and	O
Health	O
Technology	O
Tays	O
Cancer	O
Centre	O
Tampere	O
University	O
P.O.	O
Box	O
100	O
FI-33014	O
Tampere	O
Finland	O
Department	O
of	O
Oncology	O
Tampere	O
University	O
Hospital	O
P.O.	O
Box	O
2000	O
FI-33521	O
Tampere	O
Finland	O
OutiLahdenperä	B-authors
PiaVihinen	B-authors
ArjaJukkola	B-authors
PeeterKarihtala	B-authors
SonjaAho	O
Department	O
of	O
Oncology	O

Faculty	O
of	O
Medicine	O
and	O
Health	O
Technology	O
Tays	O
Cancer	O
Centre	O
Tampere	O
University	O
P.O.	O
Box	O
100	O
FI-33014	O
Tampere	O
Finland	O
Department	O
of	O
Oncology	O
Tampere	O
University	O
Hospital	O
P.O.	O
Box	O
2000	O
FI-33521	O
Tampere	O
Finland	O
EevaMoilanen	B-authors
KariAlitalo	B-authors

Faculty	O
of	O
Medicine	O
and	O
Health	O
Technology	O
Tays	O
Cancer	O
Centre	O
Tampere	O
University	O
P.O.	O
Box	O
100	O
FI-33014	O
Tampere	O
Finland	O
Department	O
of	O
Oncology	O
Tampere	O
University	O
Hospital	O
P.O.	O
Box	O
2000	O
FI-33521	O
Tampere	O
Finland	O

Faculty	O
of	O
Medicine	O
and	O
Health	O
Technology	O
Tays	O
Cancer	O
Centre	O
Tampere	O
University	O
P.O.	O
Box	O
100	O
FI-33014	O
Tampere	O
Finland	O
Department	O
of	O
Oncology	O
Tampere	O
University	O
Hospital	O
P.O.	O
Box	O
2000	O
FI-33521	O
Tampere	O
Finland	O
EmiliaAKorhonen	B-authors

Faculty	O
of	O
Medicine	O
and	O
Health	O
Technology	O
Tays	O
Cancer	O
Centre	O
Tampere	O
University	O
P.O.	O
Box	O
100	O
FI-33014	O
Tampere	O
Finland	O
Department	O
of	O
Oncology	O
Tampere	O
University	O
Hospital	O
P.O.	O
Box	O
2000	O
FI-33521	O
Tampere	O
Finland	O
OutiLahdenperä	B-authors
PiaVihinen	B-authors
ArjaJukkola	B-authors
PeeterKarihtala	B-authors
SonjaAho	O
Department	O
of	O
Oncology	O

Faculty	O
of	O
Medicine	O
and	O
Health	O
Technology	O
Tays	O
Cancer	O
Centre	O
Tampere	O
University	O
P.O.	O
Box	O
100	O
FI-33014	O
Tampere	O
Finland	O
Department	O
of	O
Oncology	O
Tampere	O
University	O
Hospital	O
P.O.	O
Box	O
2000	O
FI-33521	O
Tampere	O
Finland	O
EevaMoilanen	B-authors
KariAlitalo	B-authors

Faculty	O
of	O
Medicine	O
and	O
Health	O
Technology	O
Tays	O
Cancer	O
Centre	O
Tampere	O
University	O
P.O.	O
Box	O
100	O
FI-33014	O
Tampere	O
Finland	O
Department	O
of	O
Oncology	O
Tampere	O
University	O
Hospital	O
P.O.	O
Box	O
2000	O
FI-33521	O
Tampere	O
Finland	O

Faculty	O
of	O
Medicine	O
and	O
Health	O
Technology	O
Tays	O
Cancer	O
Centre	O
Tampere	O
University	O
P.O.	O
Box	O
100	O
FI-33014	O
Tampere	O
Finland	O
Department	O
of	O
Oncology	O
Tampere	O
University	O
Hospital	O
P.O.	O
Box	O
2000	O
FI-33521	O
Tampere	O

0000	O
-	O
0003	O
-	O
4247	O
-	O
8523	O
EmiliaAKorhonen	O
Emilia	O
A	O
Korhonen	O
0000	O
-	O
0003	O
-	O
4247	O
-	O
8523	O
Veli	B-authors
-	I-authors
MattiLeppänen	I-authors
Veli	B-authors
-	I-authors
MattiLeppänen	I-authors
Veli	B-authors
-	I-authors
Matti	I-authors
Leppänen	I-authors
TiinaLuukkaala	B-authors
TiinaLuukkaala	B-authors
Tiina	B-authors
Luukkaala	I-authors
MariHämäläinen	B-authors
MariHämäläinen	B-authors
Mari	B-authors
Hämäläinen	I-authors
MinnaTanner	B-authors
Department	O
of	O
Oncology	O

Faculty	O
of	O
Medicine	O
and	O
Health	O
Technology	O
Tays	O
Cancer	O
Centre	O
Tampere	O
University	O
P.O.	O
Box	O
100	O
FI-33014	O
Tampere	O
Finland	O
Department	O
of	O
Oncology	O
Tampere	O
University	O
Hospital	O
P.O.	O
Box	O
2000	O
FI-33521	O
Tampere	O

Finland	O
P.O.	O
Box	O
2000	O
FI-33521	O
Tampere	O
Finland	O
OutiLahdenperä	B-authors
OutiLahdenperä	B-authors
Outi	B-authors
Lahdenperä	I-authors
PiaVihinen	B-authors
PiaVihinen	B-authors
Pia	B-authors
Vihinen	I-authors
ArjaJukkola	B-authors
ArjaJukkola	B-authors
Arja	B-authors
Jukkola	I-authors
PeeterKarihtala	B-authors
PeeterKarihtala	B-authors
Peeter	B-authors
Karihtala	I-authors
SonjaAho	B-authors
Department	O
of	O
Oncology	O

Faculty	O
of	O
Medicine	O
and	O
Health	O
Technology	O
Tays	O
Cancer	O
Centre	O
Tampere	O
University	O
P.O.	O
Box	O
100	O
FI-33014	O
Tampere	O
Finland	O
Department	O
of	O
Oncology	O
Tampere	O
University	O
Hospital	O
P.O.	O
Box	O
2000	O
FI-33521	O
Tampere	O

Faculty	O
of	O
Medicine	O
and	O
Health	O
Technology	O
Tays	O
Cancer	O
Centre	O
Tampere	O
University	O
P.O.	O
Box	O
100	O
FI-33014	O
Tampere	O
Finland	O
Department	O
of	O
Oncology	O
Tampere	O
University	O
Hospital	O
P.O.	O
Box	O
2000	O
FI-33521	O
Tampere	O

Finland	O
P.O.	O
Box	O
2000	O
FI-33521	O
Tampere	O
Finland	O
High	O
baseline	O
Tie1	O
level	O
predicts	O
poor	O
survival	O
in	O
metastatic	O
breast	O
cancer	O
10.1186	O
/	O
s12885	O
-	O
019	O
-	O
5959	O
-	O
8	O
Received	O
:	O
20	O
September	O
2018	O
Accepted	O
:	O
19	O
July	O
2019	O

Several	O
drugs	O
targeting	O
the	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
VEGF	O
receptors	O
(	O
VEGFR	O
)	O
are	O
currently	O
used	O
as	O
treatment	O
of	O
various	O
cancer	O
types	O
in	O
clinics	O
[	O
1	O
]	O
.	O
VEGF	O
targeting	O
antibodies	O
alleviate	O
age	O
-	O
related	O
macular	O
degeneration	O
,	O
but	O
in	O
cancer	O
therapy	O
,	O
they	O
provide	O
only	O
limited	O
benefits	O
.	O
For	O
this	O
reason	O
,	O
a	O
significant	O
interest	O
has	O
emerged	O
in	O
the	O
targeting	O
of	O
the	O
more	O
recently	O
characterized	O
Ang	O
/	O
Tie	O
endothelial	O
growth	O
factor	O
system	O
,	O
which	O
has	O
essential	O
functions	O
in	O
embryonic	O
development	O
,	O
the	O
regeneration	O
of	O
the	O
mature	O
vasculature	O
,	O
tissue	O
inflammation	O
and	O
tumor	O
angiogenesis	O
[	O
2][3][4][5][6	O
]	O
.	O
Angiopoietin	O
growth	O
factors	O
(	O
Ang1	O
-	O
4	O
)	O
bind	O
to	O
the	O
Tie2	O
receptor	O
.	O
The	O
homologous	O
Tie1	O
protein	O
does	O
not	O
bind	O
angiopoietins	O
directly	O
,	O
although	O
it	O
participates	O
in	O
the	O
Ang	O
-	O
Tie2	O
signal	O
transduction	O
complex	O
[	O
2,[6][7][8	O
]	O
.	O

Ang1	O
stabilizes	O
the	O
vasculature	O
after	O
angiogenesis	O
and	O
is	O
a	O
more	O
potent	O
Tie2	O
agonist	O
than	O
Ang2	O
,	O
which	O
can	O
act	O
as	O
an	O
agonist	O
or	O
antagonist	O
of	O
the	O
Tie2	O
receptor	O
,	O
depending	O
on	O
a	O
number	O
of	O
other	O
factors	O
[	O
9][10][11	O
]	O
.	O
In	O
normal	O
homeostasis	O
,	O
Ang2	O
levels	O
are	O
low	O
,	O
but	O
the	O
Ang2	O
/	O
Ang1	O
ratio	O
is	O
increased	O
in	O
inflamed	O
tissues	O
,	O
e.g.	O
in	O
sepsis	O
and	O
in	O
malignancies	O
,	O
including	O
breast	O
cancer	O
[	O
12,13	O
]	O
.	O
High	O
Ang2	O
levels	O
are	O
associated	O
with	O
poor	O
patient	O
survival	O
in	O
multiple	O
malignancies	O
,	O
breast	O
cancer	O
among	O
others	O
[	O
14][15][16][17][18][19	O
]	O
.	O
Some	O
of	O
the	O
Ang	O
/	O
Tie	O
system	O
targeted	O
antibodies	O
have	O
already	O
been	O
evaluated	O
in	O
clinical	O
trials	O
,	O
but	O
so	O
far	O
,	O
the	O
effects	O
of	O
anti	O
-	O
Ang2	O
monotherapy	O
have	O
been	O
modest	O
[	O
20][21][22	O
]	O
.	O
A	O
better	O
understanding	O
of	O
Ang	O
function	O
is	O
clearly	O
needed	O
for	O
the	O
rational	O
development	O
of	O
effective	O
Ang	O
-	O
pathway	O
targeted	O
therapies	O
.	O
Although	O
Tie1	O
expression	O
in	O
endothelial	O
cells	O
is	O
increased	O
in	O
tumor	O
vessels	O
and	O
deletion	O
of	O
the	O
Tie1	O
gene	O
in	O
tumor	O
-	O
bearing	O
mice	O
decreased	O
tumor	O
growth	O
and	O
angiogenesis	O
in	O
preclinical	O
experiments	O
[	O
4,23	O
]	O
,	O
the	O
significance	O
of	O
Tie1	O
in	O
tumor	O
progression	O
is	O
also	O
unclear	O
.	O
Tie1	O
ectodomain	O
cleavage	O
occurs	O
in	O
vivo	O
in	O
association	O
with	O
acute	O
[	O
11	O
]	O
and	O
chronic	O
inflammation	O
[	O
24	O
]	O
,	O
leading	O
to	O
increased	O
concentration	O
of	O
the	O
soluble	O
extracellular	O
domain	O
in	O
the	O
serum	O
of	O
patients	O
with	O
severe	O
viral	O
infections	O
[	O
11	O
]	O
.	O
Furthermore	O
,	O
Tie1	O
deletion	O
in	O
a	O
murine	O
metastasis	O
model	O
tightened	O
endothelial	O
barrier	O
and	O
therefore	O
,	O
reduced	O
metastatic	O
foci	O
[	O
25	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
prognostic	O
value	O
of	O
the	O
circulating	O
levels	O
of	O
Tie1	B-arm_description
and	O
Ang2	B-arm_description
in	O
patients	O
who	O
received	O
first	O
-	O
line	O
taxane	B-arm_description
-	I-arm_description
bevacizumab	I-arm_description
combination	I-arm_description
-chemotherapy	O
combination	O
for	O
the	O
treatment	O
of	O
metastatic	O
breast	O
cancer	O
.	O
Additionally	O
,	O
we	O
explored	O
if	O
a	O
combined	O
analysis	O
of	O
Tie1	O
and	O
Ang2	B-arm_description
levels	O
would	O
help	O
to	O
identify	O
the	O
patients	O
with	O
poor	O
prognosis	O
in	O
need	O
of	O
novel	O
treatment	O
approaches	O
.	O

All	O
together	O
65	O
patients	O
with	O
histologically	O
verified	O
HER2-negative	O
advanced	O
breast	O
cancer	O
were	O
enrolled	O
into	O
the	O
single	B-study_type
-	I-study_type
arm	I-study_type
,	I-study_type
prospective	I-study_type
,	I-study_type
phase	I-study_type
2	I-study_type
study	I-study_type
in	O
three	O
Finnish	O
university	O
cancer	O
clinics	O
between	O
May	O
2009	O
and	O
October	O
2013	O
(	O
NCT00979641	O
)	O
.	O
The	O
method	O
of	O
patient	O
recruitment	O
,	O
the	O
study	O
design	O
and	O
the	O
clinical	O
trial	O
results	O
were	O
previously	O
published	O
[	O
26	O
]	O
.	O
Briefly	O
,	O
patients	O
included	O
in	O
the	O
study	O
received	O
a	O
taxane	B-arm_description
(	O
paclitaxel	B-arm_dosage
90	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
on	I-arm_dosage
days	I-arm_dosage
1	I-arm_dosage
,	I-arm_dosage
8	I-arm_dosage
and	I-arm_dosage
15	I-arm_dosage
or	I-arm_dosage
docetaxel	I-arm_dosage
50	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
on	I-arm_dosage
days	I-arm_dosage
1	I-arm_dosage
and	I-arm_dosage
15	I-arm_dosage
)	O
with	O
bevacizumab	B-arm_description
(	O
10	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
kg	I-arm_dosage
on	I-arm_dosage
days	I-arm_dosage
1	I-arm_dosage
and	I-arm_dosage
15	I-arm_dosage
)	O
on	O
a	O
treatment	B-arm_dosage
cycle	I-arm_dosage
of	I-arm_dosage
4	I-arm_dosage
weeks	I-arm_dosage
as	O
the	O
first	O
-	O
line	O
chemotherapy	O
for	O
metastatic	O
breast	O
cancer	O
.	O
Docetaxel	O
was	O
given	O
to	O
32	O
patients	O
and	O
33	O
patients	O
received	O
paclitaxel	O
.	O

Bevacizumab	B-arm_description
15	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
kg	I-arm_dosage
every	I-arm_dosage
three	I-arm_dosage
weeks	I-arm_dosage
was	O
continued	O
as	O
maintenance	O
therapy	O
for	O
those	O
patients	O
with	O
non	O
-	O
progressive	O
disease	O
after	O
taxane	O
discontinuation	O
.	O
In	O
addition	O
to	O
bevacizumab	O
,	O
patients	O
with	O
hormone	O
receptor	O
-	O
positive	O
disease	O
received	O
endocrine	O
therapy	O
.	O
Furthermore	O
,	O
bevacizumab	O
could	O
be	O
continued	O
with	O
second	O
-	O
line	O
chemotherapy	O
.	O
All	O
patients	O
provided	O
written	O
informed	O
consent	O
and	O
the	O
regional	O
Ethics	O
Committee	O
approved	O
the	O
study	O
protocol	O
(	O
R08142	O
M	O
)	O
.	O

Blood	O
samples	O
were	O
obtained	O
from	O
the	O
patients	O
during	O
treatment	O
.	O
EDTA	O
samples	O
for	O
plasma	O
analysis	O
were	O
obtained	O
at	O
the	O
baseline	O
,	O
every	O
6	O
weeks	O
during	O
the	O
bevacizumab	B-arm_description
-	I-arm_description
taxane	I-arm_description
combination	I-arm_description
,	O
at	O
the	O
discontinuation	O
of	O
taxane	B-arm_description
treatment	O
,	O
during	O
the	O
bevacizumab	B-arm_description
maintenance	O
therapy	O
,	O
first	O
every	O
three	O
weeks	O
for	O
the	O
first	O
two	O
months	O
and	O
thereafter	O
every	O
12	O
weeks	O
,	O
and	O
at	O
the	O
final	O
study	O
visit	O
.	O

Healthy	O
control	O
samples	O
were	O
obtained	O
from	O
10	O
women	O
participating	O
in	O
a	O
mammography	O
screening	O
program	O
at	O
the	O
Hatanpää	O
Breast	O
Clinic	O
in	O
Tampere	O
.	O
These	O
women	O
voluntarily	O
participated	O
in	O
a	O
breast	O
cancer	O
primary	O
prevention	O
study	O
currently	O
in	O
progress	O
at	O
the	O
University	O
of	O
Tampere	O
and	O
,	O
as	O
a	O
part	O
of	O
the	O
accepted	O
protocol	O
,	O
blood	O
samples	O
were	O
drawn	O
for	O
scientific	O
purposes	O
.	O
All	O
participants	O
gave	O
their	O
written	O
informed	O
consent	O
and	O
the	O
regional	O
Ethics	O
Committee	O
approved	O
the	O
study	O
(	O
R15023	O
)	O
.	O

The	O
patient	O
population	O
and	O
the	O
analyzed	O
plasma	O
samples	O
were	O
identical	O
to	O
our	O
previous	O
paper	O
focusing	O
on	O
plasma	O
interleukin-8	O
levels	O
as	O
a	O
prognostic	O
marker	O
[	O
27	O
]	O
.	O
At	O
the	O
baseline	O
,	O
plasma	O
samples	O
were	O
available	O
from	O
53	O
patients	O
(	O
82	O
%	O
)	O
.	O
Overall	O
,	O
plasma	O
samples	O
were	O
available	O
from	O
58	O
(	O
89	O
%	O
)	O
of	O
the	O
65	O
patients	O
treated	O
in	O
the	O
study	O
.	O
Key	O
characteristics	O
of	O
the	O
study	O
population	O
and	O
the	O
main	O
efficacy	O
outcomes	O
are	O
presented	O
in	O
Table	O
1	O
.	O
Plasma	O
samples	O
for	O
Tie1	B-arm_description
and	O
Ang2	B-arm_description
were	O
analyzed	O
at	O
four	O
time	O
points	O
:	O
at	O
the	O
baseline	O
,	O
six	O
weeks	O
after	O
the	O
treatment	O
initiation	O
,	O
six	O
months	O
after	O
the	O
treatment	O
initiation	O
and	O
at	O
the	O
final	O
visit	O
.	O
The	O
number	O
of	O
patients	O
that	O
had	O
plasma	O
samples	O
analyzed	O
and	O
the	O
reasons	O
for	O
exclusions	O
are	O
presented	O
in	O
a	O
flow	O
chart	O
(	O
Fig	O
.	O
1	O
)	O
.	O
Six	O
weeks	O
'	O
and	O
six	O
months	O
'	O
samples	O
were	O
available	O
only	O
for	O
those	O
patients	O
that	O
were	O
still	O
on	O
study	O
treatment	O
at	O
that	O
time	O
point	O
.	O

The	O
median	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
were	O
similar	O
for	O
patients	O
treated	O
with	O
docetaxel	O
or	O
paclitaxel	O
(	O
PFS	O
:	O
p	O
=	O
0.47	O
,	O
OS	O
:	O
p	O
=	O
0.77	O
)	O
.	O
The	O
median	O
OS	O
for	O
patients	O
with	O
triple	O
-	O
negative	O
breast	O
cancer	O
was	O
17.9	O
months	O
(	O
95	O
%	O
CI	O
8.5	O
-	O
26.9	O
)	O
.	O
Furthermore	O
,	O
the	O
median	O
OS	O
for	O
patients	O
with	O
hormone	O
receptor	O
positive	O
metastatic	O
breast	O
cancer	O
was	O
45.0	O
months	O
(	O
95	O
%	O
CI	O
30.2	O
-	O
51.3	O
)	O
.	O

The	O
statistical	O
plan	O
for	O
the	O
biomarker	O
analysis	O
was	O
exploratory	O
.	O
Tie1	B-arm_description
and	O
Ang2	B-arm_description
were	O
dichotomized	O
as	O
low	O
or	O
high	O
for	O
each	O
patient	O
using	O
the	O
median	O
value	O
as	O
the	O
cutoff	O
.	O
Sensitivity	O
,	O
specificity	O
and	O
area	O
under	O
curve	O
(	O
AUC	O
)	O
for	O
plasma	O
Tie1	O
concentration	O
were	O
determined	O
using	O
receiver	O
operator	O
characteristic	O
(	O
ROC	O
)	O
analysis	O
.	O
Baseline	O
Tie1	B-arm_description
or	O
Ang2	B-arm_description
levels	O
as	O
independent	O
prognostic	O
factors	O
(	O
below	O
/	O
above	O
median	O
)	O
were	O
evaluated	O
using	O
Cox	O
proportional	O
hazard	O
regression	O
analysis	O
.	O
Multivariate	O
analysis	O
was	O
performed	O
using	O
the	O
Cox	O
model	O
,	O
and	O
it	O
was	O
adjusted	O
by	O
age	O
(	O
continuous	O
)	O
,	O
menopausal	O
status	O
(	O
yes	O
/	O
no	O
)	O
,	O
hormone	O
receptor	O
status	O
(	O
negative	O
/	O
positive	O
)	O
,	O
presence	O
of	O
visceral	O
metastasis	O
(	O
yes	O
/	O
no	O
)	O
,	O
number	O
of	O
metastatic	O
lesions	O
(	O
cut	O
-	O
off	O
of	O
three	O
metastatic	O
lesions	O
)	O
and	O
extent	O
of	O
the	O
disease	O
(	O
cutoff	O
of	O
three	O
metastatic	O
sites	O
)	O
.	O
The	O
Mann	O
-	O
Whitney	O
U	O
test	O

For	O
the	O
study	O
population	O
,	O
the	O
median	O
Tie1	B-arm_description
level	O
at	O
baseline	O
was	O
21.0	O
ng	O
/	O
ml	O
(	O
95	O
%	O
CI	O
17.8	O
-	O
23.3	O
,	O
Fig	O
.	O
2a	O
)	O
,	O
and	O
the	O
median	O
Ang2	B-arm_description
level	O
at	O
baseline	O
was	O
1.29	O
ng	O
/	O
ml	O
(	O
95	O
%	O
CI	O
1.03	O
-	O
1.52	O
,	O
Fig	O
.	O
2b	O
)	O
.	O
The	O
baseline	O
Tie1	B-arm_description
levels	O
were	O
significantly	O
lower	O
in	O
the	O
healthy	O
controls	O
than	O
in	O
the	O
metastatic	O
breast	O
cancer	O
patients	O
(	O
Fig	O
.	O
2a	O
)	O
.	O
The	O
median	O
Tie1	B-arm_description
level	O
for	O
healthy	O
controls	O
was	O
12.8	O
ng	O
/	O
ml	O
(	O
95	O
%	O
CI	O
10.4	O
-	O
16.5	O
,	O
Fig	O
.	O
2a	O
)	O
.	O
The	O
most	O
optimal	O
cut	O
-	O
off	O
value	O
(	O
16.0	O
ng	O
/	O
ml	O
)	O
for	O
plasma	O
Tie1	B-arm_description
concentration	O
had	O
a	O
sensitivity	O
of	O
77.4	O
%	O
,	O
but	O
a	O
specificity	O
of	O
only	O
30.0	O
%	O
,	O
for	O
distinguishing	O
metastatic	O
breast	O
cancer	O
patients	O
from	O
healthy	O
controls	O
with	O
an	O
AUC	O
0.917	O
(	O
95	O
%	O
CI	O
0.839	O
-	O
0.995	O
,	O
p	O
<	O
0.001	O
)	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
baseline	O
Tie1	B-arm_description
or	O
Ang2	B-arm_description
levels	O
between	O
groups	O
with	O
different	O
baseline	O
characteristics	O
,	O
including	O
menopausal	O
status	O
(	O
p	O
=	O
0.09	O
for	O
Tie1	B-arm_description
,	O
p	O
=	O
0.13	O
for	O
Ang2	B-arm_description
)	O
,	O
hormone	O
receptor	O
status	O
(	O
p	O
=	O
0.80	O
for	O
Tie1	B-arm_description
,	O
p	O
=	O
0.14	O
for	O
Ang2	B-arm_description
)	O
,	O
number	O
of	O
metastatic	O
lesions	O
(	O
p	O
=	O
0.69	O
for	O
Tie1	B-arm_description
,	O
p	O
=	O
0.37	O
for	O
Ang2	B-arm_description
)	O
or	O
visceral	O
disease	O
(	O
p	O
=	O
0.92	O
for	O
Tie1	B-arm_description
,	O
p	O
=	O
0.15	O
for	O
Ang2	B-arm_description
)	O
.	O
Only	O
the	O
patients	O
with	O
more	O
than	O
three	O
metastatic	O
sites	O
had	O
significantly	O
higher	O
baseline	O
Tie1	B-arm_description
levels	O
than	O
the	O
patients	O
with	O
fewer	O
metastatic	O
sites	O
(	O
median	O
Tie1	B-arm_description
23.7	O
ng	O
/	O
ml	O
,	O
95	O
%	O
CI	O
21.0	O
-	O
29.0	O
vs.	O
17.8	O
ng	O
/	O
ml	O
,	O
95	O
%	O
CI	O
16.0	O
-	O
21.1	O
,	O
p	O
=	O
0.002	O
)	O
.	O
Similarly	O
,	O
the	O
patients	O
with	O
more	O
than	O
three	O
metastatic	O
sites	O
had	O
significantly	O
higher	O
baseline	O
Ang2	B-arm_description
levels	O
(	O
median	O
Ang2	B-arm_description
1.08	O
ng	O
/	O
ml	O
,	O
95	O
%	O
CI	O
0.66	O
-	O
1.36	O
vs.	O
1.54	O
ng	O
/	O
ml	O
,	O
95	O
%	O
CI	O
1.23	O
-	O
2.29	O
,	O
p	O
=	O
0.008	O
)	O
.	O

Differences	O
in	O
Tie1	B-arm_description
and	O
Ang2	B-arm_description
concentrations	O
between	O
baseline	O
and	O
week	O
six	O
samples	O
were	O
analyzed	O
to	O
evaluate	O
the	O
treatment	O
effect	O
.	O
The	O
median	O
baseline	O
Tie1	B-arm_description
level	O
was	O
21.0	O
ng	O
/	O
ml	O
(	O
95	O
%	O
CI	O
17.8	O
-	O
23.3	O
)	O
,	O
which	O
was	O
significantly	O
higher	O
than	O
the	O
median	O
Tie1	B-arm_description
level	O
at	O
six	O
weeks	O
(	O
15.4	O
ng	O
/	O
ml	O
[	O
95	O
%	O
CI	O
14.1	O
-	O
17.1	O
]	O
,	O
p	O
<	O
0.001	O
,	O
Fig	O
.	O
2a	O
)	O
.	O
The	O
median	O
decrease	O
in	O
the	O
Tie1	B-arm_description
level	O
between	O
these	O
two	O
time	O
points	O
was	O
22.9	O
%	O
(	O
95	O
%	O
CI	O
20.9	O
-	O
27.4	O
)	O
.	O
The	O
median	O
baseline	O
Ang2	B-arm_description
level	O
was	O
1.29	O
ng	O
/	O
ml	O
(	O
95	O
%	O
CI	O
1.03	O
-	O
1.52	O
)	O
and	O
the	O
median	O
Ang2	B-arm_description
level	O
at	O
six	O
weeks	O
was	O
0.62	O
ng	O
/	O
ml	O
(	O
95	O
%	O
CI	O
0.57	O
-	O
0.84	O
)	O
.	O
The	O
median	O
decrease	O
in	O
the	O
levels	O
of	O
Ang2	B-arm_description
from	O
the	O
baseline	O
to	O
six	O
weeks	O
,	O
47.0	O
%	O
(	O
95	O
%	O
CI	O
34.5	O
-	O
52.9	O
)	O
,	O
was	O
also	O
statistically	O
significant	O
(	O
p	O
<	O
0.001	O
,	O
Fig	O
.	O
2b	O
)	O
.	O

Median	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
was	O
longer	O
for	O
patients	O
in	O
the	O
low	O
baseline	O
Tie1	O
level	O
group	O
than	O
for	O
the	O
patients	O
in	O
the	O
high	O
baseline	O
Tie1	B-arm_description
group	O
(	O
Fig	O
.	O
3a	O
,	O
Table	O
2	O
)	O
.	O
No	O
difference	O
was	O
observed	O
in	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
in	O
relation	O
to	O
baseline	O
Ang2	B-arm_description
levels	O
(	O
Fig	O
.	O
3b	O
,	O
Table	O
2	O
)	O
.	O

The	O
overall	O
survival	O
was	O
significantly	O
shorter	O
for	O
patients	O
with	O
a	O
high	O
baseline	O
Tie1	B-arm_description
concentration	O
(	O
Fig	O
.	O
3c	O
,	O
Table	O
3	O
)	O
.	O
Additionally	O
,	O
patients	O
with	O
high	O
baseline	O
Ang2	B-arm_description
levels	O
had	O
shorter	O
overall	O
survival	O
when	O
analyzed	O
by	O
the	O
age	O
-	O
adjusted	O
Cox	O
hazard	O
regression	O
model	O
(	O
Table	O
3	O
)	O
.	O
However	O
,	O
in	O
a	O
multivariate	O
Cox	O
model	O
adjusted	O
by	O
age	O
,	O
menopausal	O
status	O
,	O
hormone	O
receptor	O
status	O
,	O
presence	O
of	O
visceral	O
metastases	O
,	O
number	O
of	O
metastatic	O
lesions	O
and	O
extent	O
of	O
disease	O
,	O
a	O
high	O
baseline	O
levels	O
of	O
Ang2	B-arm_description
alone	O
was	O
not	O
a	O
significant	O
factor	O
for	O
poor	O
prognosis	O
(	O
Fig	O
.	O
3d	O
,	O
Table	O
3	O
)	O
.	O

For	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
,	O
the	O
combined	O
analysis	O
of	O
baseline	O
Tie1	B-arm_description
and	O
Ang2	B-arm_description
levels	O
did	O
not	O
add	O
any	O
value	O
compared	O
to	O
the	O
Tie1	B-arm_description
analysis	O
on	O
its	O
own	O
(	O
Fig	O
.	O
4a	O
,	O
Table	O
2	O
)	O
.	O
However	O
,	O
the	O
combined	O
analysis	O
for	O
high	O
or	O
low	O
baseline	O
Fig	O
.	O
1	O
Flow	O
diagram	O
of	O
study	O
patient	O
plasma	O
samples	O
analyzed	O
at	O
baseline	O
,	O
after	O
six	O
weeks	O
'	O
treatment	O
,	O
after	O
six	O
months	O
'	O
treatment	O
and	O
at	O
final	O
visit	O
.	O
Final	O
plasma	O
samples	O
were	O
taken	O
at	O
the	O
final	O
study	O
visit	O
and	O
the	O
reasons	O
for	O
discontinuation	O
are	O
presented	O
in	O
the	O
chart	O
Tie1	B-arm_description
and	O
Ang2	B-arm_description
levels	O
was	O
more	O
effective	O
in	O
the	O
selection	O
of	O
patients	O
with	O
better	O
overall	O
survival	O
(	O
Fig	O
.	O
4b	O
,	O
Table	O
3	O
)	O
.	O
The	O
median	O
overall	O
survival	O
for	O
patients	O
with	O
low	O
baseline	O
levels	O
of	O
both	O
Tie1	B-arm_description
and	O
Ang2	B-arm_description
was	O
46.8	O
months	O
(	O
95	O
%	O
CI	O
23.8	O
-	O
79.8	O
)	O
.	O
In	O
contrast	O
,	O
the	O
median	O
overall	O
survival	O
for	O
patients	O
with	O
high	O
baseline	O
levels	O
of	O
both	O
Tie1	B-arm_description
and	O
Ang2	B-arm_description
was	O
only	O
21.5	O
months	O
(	O
95	O
%	O
CI	O
8.8	O
-	O
34.7	O
)	O
.	O

The	O
median	O
decline	O
in	O
Ang2	B-arm_description
levels	O
between	O
baseline	O
and	O
week	O
six	O
was	O
47.0	O
%	O
.	O
The	O
patients	O
with	O
Ang2	B-arm_description
level	O
decline	O
higher	O
than	O
the	O
median	O
value	O
had	O
significantly	O
worse	O
prognoses	O
.	O
Multivariate	O
Hazard	O
Ratio	O
(	O
HR	O
)	O
for	O
overall	O
survival	O
was	O
4.53	O
(	O
95	O
%	O
CI	O
1.82	O
-	O
11.27	O
,	O
p	O
=	O
0.001	O
)	O
.	O
In	O
contrast	O
,	O
a	O
high	O
Tie1	B-arm_description
decline	O
during	O
the	O
first	O
six	O
weeks	O
of	O
treatment	O
was	O
not	O
prognostic	O
.	O
The	O
median	O
Tie1	B-arm_description
decline	O
during	O
this	O
time	O
period	O
was	O
22.9	O
%	O
.	O
The	O
patients	O
had	O
similar	O
survival	O
whether	O
they	O
had	O
Tie1	B-arm_description
decline	O
higher	O
or	O
lower	O
than	O
median	O
value	O
between	O
baseline	O
and	O
week	O
six	O
(	O
multivariate	O
HR	O
for	O
overall	O
survival	O
1.04	O
,	O
95	O
%	O
CI	O
0.46	O
-	O
2.33	O
,	O
p	O
=	O
0.921	O
)	O
.	O

Only	O
seven	O
patients	O
,	O
i.e.	O
14	O
%	O
of	O
the	O
patients	O
whose	O
final	O
samples	O
were	O
available	O
,	O
had	O
at	O
least	O
30	O
%	O
increased	O
Tie1	B-arm_description
plasma	O
concentrations	O
at	O
their	O
final	O
visits	O
,	O
when	O
compared	O
to	O
the	O
previous	O
measurements	O
in	O
each	O
patient	O
.	O
For	O
all	O
these	O
patients	O
,	O
the	O
reason	O
for	O
study	O
discontinuation	O
was	O
disease	O
progression	O
.	O
Nevertheless	O
,	O
these	O
patients	O
had	O
a	O
similar	O
overall	O
survival	O
as	O
the	O
patients	O
with	O
stable	O
or	O
declining	O
Tie1	B-arm_description
levels	O
(	O
multivariate	O
HR	O
2.30	O
,	O
95	O
%	O
CI	O
0.90	O
-	O
5.85	O
,	O
p	O
=	O
0.078	O
)	O
.	O
At	O
least	O
30	O
%	O
increased	O
Ang2	B-arm_description
concentration	O
was	O
observed	O
in	O
24	O
patients	O
at	O
their	O
final	O
visits	O
(	O
48	O
%	O
of	O
the	O
patients	O
whose	O
final	O
samples	O
were	O
available	O
)	O
.	O
The	O
overall	O
survival	O
of	O
these	O
patients	O
was	O
significantly	O
worse	O
than	O
in	O
the	O
patients	O
with	O
stable	O
or	O
declining	O
Ang2	B-arm_description
values	O
(	O
multivariate	O
HR	O
2.17	O
,	O
95	O
%	O
CI	O
1.09	O
-	O
4.31	O
,	O
p	O
=	O
0.027	O
)	O
.	O

High	O
baseline	O
plasma	O
Tie1	B-arm_description
level	O
is	O
a	O
promising	O
prognostic	O
marker	O
for	O
both	O
poor	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
and	O
for	O
poor	O
overall	O
survival	O
in	O
metastatic	O
breast	O
patients	O
treated	O
with	O
bevacizumab	B-arm_description
-	I-arm_description
taxane	I-arm_description
combination	I-arm_description
.	O
The	O
predictive	O
value	O
of	O
circulating	O
Tie1	B-arm_description
levels	O
should	O
be	O
evaluated	O
in	O
prospective	O
clinical	O
trials	O
.	O